BCI
MRKR icon

Brinker Capital Investments’s Marker Therapeutics MRKR Stock Holding History

Brinker Capital Investments’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,173
Closed -$21K – 1407
2021
Q4 		$21K Sell
2,173
-757
-26% -$10.1K ﹤0.01% 1370
2021
Q3 		$82K Hold
2,930
– – ﹤0.01% 1272
2021
Q2 		$82K Buy
2,930
+85
+3% +$2.24K ﹤0.01% 1324
2021
Q1 		$64K Buy
+2,845
New +$65.1K ﹤0.01% 1160

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Brinker Capital Investments's MRKR Position: Q1 2022 in Review

Brinker Capital Investments sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 2,173 shares — an estimated $21K sold.

Brinker Capital Investments first reported a position in MRKR in Q1 2021 and held it in 4 quarters. The position peaked at $82K in Q3 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

  • Brinker Capital Investments reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Brinker Capital Investments sold 2,173 Marker Therapeutics shares in Q1 2022, an estimated $21K.
  • Brinker Capital Investments first reported a position in Marker Therapeutics in Q1 2021 and held it in 4 quarters.
  • Brinker Capital Investments's Marker Therapeutics position peaked at $82K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Brinker Capital Investments's 13F filing for Q1 2022, filed 16 May 2022.